Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain
George Frey, MD Becomes Aclarion’s First KOL Surgeon to Onboard a Hospital MRI to add Nociscan Data to his Treatment Decisioning Process for Chronic Low Back Pain Patients
Published Clinical Data Demonstrates That Patient Outcomes are Improved and Costs are Reduced When Surgical Treatment is Consistent With the Disc Levels Nociscan Identifies as Painful
BROOMFIELD, CO, Oct. 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their expanded footprint in Colorado with AdventHealth Porter. From their location in Denver, AdventHealth Porter provides exceptional medical care to patients throughout the front range of Colorado.
George Frey MD, Orthopedic Surgeon and founder of the Colorado Comprehensive Spine Institute said, “Treating patients effectively starts with an informed understanding of where their pain is coming from. In my experience with Nociscan, objectively measuring the biomarker content corelated with pain within a disc that may look healthy on an MRI, adds to my knowledge of how to treat that patient. At AdventHealth Porter, we are committed to provide the highest quality cost effective care possible. The published evidence is clear to me that adding Nociscan to our diagnostic evaluation may help us do that.”
Brent Ness, CEO of Aclarion, said, “In keeping with our strategy to drive Nociscan to standard of care through KOL advocacy, we applaud AdventHealth Porter in bringing Nociscan technology to Denver in support of Dr. Frey’s vision to utilize our technology to improve outcomes while lowering costs. The support of pioneering leaders like Dr. Frey and AdventHealth is exactly the leadership we need to unequivocally demonstrate the superior clinical outcomes for patients that will drive coverage decisions by payers and give all patients access to Nociscan technology. We thank Dr. Frey and AdventHealth and look forward to the positive impact increasing Nociscan volumes will have on the surgical outcomes of chronic low back patients in and around the Denver community.”
“Providing exceptional care with leading-edge treatments is a core value of our multidiscipline healthcare team here at AdventHealth Porter,” stated Carol Bermingham, Imaging Manager at AdventHealth Porter. “We are enthusiastic about adding Nociscan to our MRI capability and believe providing personalized biomarker data to treating physicians is yet another investment in our commitment to providing an environment where our doctors can do their very best for their patients. Our radiology service line is always striving to stay on the front edge of the technical advancement curve.”
Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Low back pain has been estimated to affect up to 30 million adults in the US population each year, leading to millions of physician consults per year.
Aclarion’s proprietary decision-support tool, Nociscan, is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Prospectus dated April 21, 2022, as filed with the Securities and Exchange Commission on April 25, 2022 under Rule 424(b)(4), as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
